BriaCell Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de BriaCell Therapeutics disminuyan a un ritmo anual de 28.2%, mientras que sus ingresos anuales crecerán a un ritmo de 90.9% por año. Se espera que el BPA disminuya en un 26.7% al año.

Información clave

-28.2%

Tasa de crecimiento de los beneficios

-26.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	35.8%
Tasa de crecimiento de los ingresos	90.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	04 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

We Think BriaCell Therapeutics (TSE:BCT) Needs To Drive Business Growth Carefully

Dec 01

We're Not Very Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Rate

May 07

We Think BriaCell Therapeutics (TSE:BCT) Can Afford To Drive Business Growth

Feb 05

Previsiones de crecimiento de beneficios e ingresos

TSX:BCT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
7/31/2026	N/A	-52	N/A	N/A	1
7/31/2025	N/A	-37	N/A	N/A	1
7/31/2024	N/A	-24	N/A	N/A	1
4/30/2024	N/A	-6	-31	-31	N/A
1/31/2024	N/A	-13	-31	-31	N/A
10/31/2023	N/A	-13	-28	-28	N/A
7/31/2023	N/A	-20	-24	-24	N/A
4/30/2023	N/A	-18	-16	-16	N/A
1/31/2023	N/A	-23	-16	-16	N/A
10/31/2022	N/A	0	-14	-14	N/A
7/31/2022	N/A	-27	-12	-12	N/A
4/30/2022	N/A	-42	-11	-11	N/A
1/31/2022	N/A	-30	-12	-12	N/A
10/31/2021	N/A	-41	-9	-9	N/A
7/31/2021	N/A	-14	-8	-8	N/A
4/30/2021	N/A	2	-6	-6	N/A
1/31/2021	N/A	-2	-1	-1	N/A
10/31/2020	N/A	-3	-1	-1	N/A
7/31/2020	N/A	-4	-1	-1	N/A
4/30/2020	N/A	-4	-1	-1	N/A
1/31/2020	N/A	-5	-3	-3	N/A
10/31/2019	N/A	-5	-4	-4	N/A
8/1/2019	N/A	-5	-4	-4	N/A
4/30/2019	N/A	-5	-4	-4	N/A
1/31/2019	N/A	-5	-4	-4	N/A
10/31/2018	N/A	-4	-4	-4	N/A
7/31/2018	N/A	-4	-4	-4	N/A
4/30/2018	N/A	-3	-3	-3	N/A
1/31/2018	N/A	-3	N/A	-3	N/A
10/31/2017	N/A	-3	N/A	-2	N/A
7/31/2017	N/A	-3	N/A	-2	N/A
4/30/2017	N/A	-2	N/A	-2	N/A
1/31/2017	N/A	-1	N/A	-1	N/A
10/31/2016	N/A	-2	N/A	-1	N/A
7/31/2016	N/A	-2	N/A	-1	N/A
4/30/2016	N/A	-2	N/A	-1	N/A
1/31/2016	N/A	-2	N/A	-1	N/A
10/31/2015	N/A	-3	N/A	-1	N/A
7/31/2015	N/A	-3	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BCT siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que BCT siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que BCT siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que BCT no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que BCT no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BCT se prevé que sea elevada dentro de 3 años.

BriaCell Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024

BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer

New minor risk - Shareholder dilution

Independent Director recently bought CA$2.7m worth of stock

BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.80586 million.

BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

New minor risk - Share price stability

New major risk - Negative shareholders equity

BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing

BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset

BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

BriaCell Therapeutics Corp., Annual General Meeting, Jan 30, 2024

We Think BriaCell Therapeutics (TSE:BCT) Needs To Drive Business Growth Carefully

BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND

New major risk - Financial position

BriaCell Therapeutics Corp. Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

BriaCell Therapeutics Corp. Initiates Pivotal Phase 3 Study of Bria-Imt™ in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. completed the Spin-Off of 33.33% stake in Pre-Clinical Assets of BriaCell Therapeutics Corp.

Briacell Receives National Cancer Institute Grant to Advance Its Bria-Ots™ Immunotherapy for Cancer

FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer

Independent Chairman of the Board recently bought CA$160k worth of stock

BriaCell Therapeutics Corp., Annual General Meeting, Jan 24, 2023

BriaCell Therapeutics Corp. Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting

BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing

BriaCell Therapeutics Corp. Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients

BriaCell Therapeutics Corp. Secures License for A Promising Novel Anti-Cancer Agent

We're Not Very Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Rate

BriaCell Therapeutics Corp. Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

BriaCell Advances Preparatory Work for New Bria-OTS Breast Cancer Clinical Trial

High number of new directors

BriaCell Therapeutics Corp. Adds Two Clinical Trial Sites to Accelerate Patient Enrollment

BriaCell Therapeutics Corp. Appoints Alexander Kharazi to Its Scientific Advisory Board

Director recently bought CA$549k worth of stock

Briacell Therapeutics Corp. Appoints Giuseppe Del Priore as Chief Medical Officer

Director recently bought CA$451k worth of stock

We Think BriaCell Therapeutics (TSE:BCT) Can Afford To Drive Business Growth

BriaCell Therapeutics Corp.(TSXV:BCT) dropped from S&P/TSX Venture Composite Index

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Investor sentiment improved over the past week

Investor sentiment improved over the past week

BriaCell Therapeutics Corp. Announces Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

Investor sentiment improved over the past week

Briacell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

BriaCell Therapeutics Corp. announced that it has received $27.195924 million in funding

BriaCell Therapeutics Corp. announced that it expects to receive $27.195924 million in funding

Briacell Therapeutics Corp. Provides an Update on the Overall Survival (Os) Data on Its Previously Disclosed Advanced Breast Cancer Patients

CEO, President & Director recently bought CA$325k worth of stock

BriaCell Therapeutics Corp., Annual General Meeting, May 18, 2021

BriaCell Therapeutics Corp's Common Shares Deleted from Other OTC

New 90-day high: CA$7.99

New 90-day low: CA$4.40

Briacell Presents Clinical Data At the 2020 San Antonio Breast Cancer Symposium®

BriaCell Therapeutics Corp. Appoints Martin Schmieg to Board of Directors

New 90-day low: CA$4.79

BriaCell Therapeutics Corp. announced that it has received CAD 0.265 million in funding

Briacell Therapeutics Corp. Announces Collaboration with the National Cancer Institute

New 90-day low: CA$5.25

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento